Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial-Reference-Cited by-同舟云学术

Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial

Published:2017-05 Issue:2 Volume:145 Page:340-345
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Wysham Weiya Z.,Schaffer Elisabeth M.,Coles Theresa,Roque Dario R.,Wheeler Stephanie B.,Kim Kenneth H.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference37 articles.

1. Cancer statistics, 2015;Siegel;CA Cancer J. Clin.,2015

2. Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the ‘Mario Negri’ Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group

3. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer;ten Bokkel Huinink;J. Clin. Oncol.,1997

4. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer;Mutch;J. Clin. Oncol.,2007

5. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan;Gordon;J. Clin. Oncol.,2001

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness and drug wastage of bevacizumab biosimilar with or without chemotherapy for platinum-resistant recurrent ovarian cancer;Expert Review of Pharmacoeconomics & Outcomes Research;2024-02-28

2. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer;Cochrane Database of Systematic Reviews;2023-04-18

3. Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer;British Journal of Cancer;2022-02-11

4. Cost-Effectiveness of Baricitinib Compared With Standard of Care: A Modeling Study in Hospitalized Patients With COVID-19 in the United States;Clinical Therapeutics;2021-11

5. Bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer: beyond the AURELIA trial;Translational Cancer Research;2020-04